Evidence map›Paper›PMID 30619280›Full record

ArticleFrontiers in immunology2018

Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?

Dawei Chen, Xinyu Song, Haiyong Wang, Zhenwu Gao, Wenjuan Meng, Shuquan Chen, Yunfeng Ma, Youda Wang, Kong Li, Jinming Yu and 1 more

Erratum issued Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06518018 (Exploring the Efficacy and Safety of High-Dose Rate Brachytherapy Combined With Immunotherapy and Chemotherapy as a Second-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06518018 unknown statusnot on this mapstarted 2023, after this paper: background citation

Exploring the Efficacy and Safety of High-Dose Rate Brachytherapy Combined With Immunotherapy and Chemotherapy as a Second-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Center, Retrospective, Propensity Score-Matched Study

TypeobservationalSponsorThe First People's Hospital of NeijiangRan2023 to 2025Enrolled80ConditionsAdvanced Stage NSCLC, Second-line Treatment, Patients Without Targetable Driver MutationsArmsHDR brachytherapy (30Gy single fraction), Immunotherapy
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Radiotherapy combined with immunotherapy: the dawn of cancer treatment.Signal transduction and targeted therapy · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Dawei ChenDepartment of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Xinyu SongDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Haiyong WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Zhenwu GaoDepartment of oncology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Wenjuan MengWeifang People's Hospital, Weifang, China.
Shuquan ChenLaiwu Hospital of Traditional Chinese Medicine, Laiwu, China.
Yunfeng MaLaiwu People's Hospital, Laiwu, China.
Youda WangLinyi City People's Hospital, Linyi, China.
Kong LiDepartment of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Jinming YuDepartment of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China.
Shandong First Medical University · CNShandong Tumor Hospital · CNJinan City People's Hospital · CNLinyi People's Hospital · CNShandong University · CNWeifang Medical University · CNWeifang People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical and clinical studies have shown that prior receipt of radiotherapy enhances antitumor immune responses, a phenomenon we call the "radio-memory effect." However, all of the evidence regarding this effect to date comes from work with PD1/PDL1 inhibitors. Here we explored whether this effect also occurs with other forms of immune therapy, specifically interleukin-2 (IL-2). We retrospectively assessed outcomes in patients with malignant pleural effusion (MPE) who had previously received radiotherapy for non-small-cell lung cancer (NSCLC) within 18 months before the intrapleural infusion of IL-2 or cisplatin. Radiotherapy sites included lungs, thoracic lymph nodes, and intracranial. All patients received intrapleural infusion of IL-2 or cisplatin, and most had had several cycles of standard chemotherapy for NSCLC. We identified 3,747 patients with MPE (median age 64 years [range 29-88)) treated at one of several institutions from August 2009 through February 2015; 642 patients had been treated with IL-2 and 1102 with cisplatin and had survived for at least 6 months afterward. Among those who received IL-2, 288 had no radiotherapy, 324 had extracranial (i.e., thoracic) radiotherapy, and 36 had intracranial radiotherapy. The median follow-up time for surviving patients was 38 months. Patients who had received extracranial radiotherapy followed by IL-2 had significantly longer PFS than patients who had not received extracranial radiotherapy (i.e., either no radiotherapy or intracranial radiotherapy). Patients who had received intracranial or extracranial radiotherapy followed by IL-2 had significantly longer OS than did other patients. No survival advantage was noted for prior radiotherapy among patients who received intrapleural cisplatin. We speculate that previous radiotherapy could enhance the efficacy of subsequent intrapleural infusion of IL-2, a "radio-memory" effect that could be beneficial in future studies.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCisplatinFemaleHumansImmunologic MemoryInterleukin-2Kaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPleural Effusion, MalignantRadiotherapyAntineoplastic AgentsCisplatinInterleukin-2immunotherapyinterleukin-2 (IL-2)malignant pleural effusion (MPE)non-small-cell lung cancer (NSCLC)radio-memory effectradiotherapy

Identifiers

PMID30619280
PMCPMC6297715
OpenAlexW4232514058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.